You have 0 free articles left this month.
Big Law

Microba Life Sciences lists on ASX

Gut health business Microba Life Sciences (ASX: MAP) has successfully listed on the Australian Securities Exchange, in an initial public offering that raised $30 million.

April 20, 2022 • By Jerome Doraisamy
Share this article on:
facebook Facebook twitter X linkedin LinkedIn
Microba Life Sciences
expand image

Firm: Thomson Geer (Microba Life Sciences)

This content is available exclusively to Lawyers Weekly premium members.
Deal: Microba has listed on the ASX following a $30 million IPO and was advised by Thomson Geer on all aspects of the listing, including legal requirements in relation to the prospectus and the due diligence process.

The IPO was backed by New York Stock Exchange-listed synthetic biology company Ginkgo Bioworks, which is backed by Bill Gates.

Area: Corporate, M&A

Value: $30 million

Key players: The Thomson Geer team was led by partner Emma Cook, who was supported by Belinda Pinnow and Robin Mahly.

Deal significance: Ms Cook said: “We were pleased to have been able to help Microba list on the ASX and enable investors to support its work in human health.”

The Lawyers Weekly Jobs Board has had a refresh! To check out the latest opportunities in private practice, in-house and more, click here.

Jerome Doraisamy
Jerome Doraisamy

Jerome Doraisamy is the managing editor of Lawyers Weekly and HR Leader. He is also the author of The Wellness Doctrines book series, an admitted solicitor in New South Wales, and a board director of the Minds Count Foundation.

You can email Jerome at: This email address is being protected from spambots. You need JavaScript enabled to view it. 

Tags
You need to be a member to post comments. Become a member today